Evidence map›Paper›PMID 39705633›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2025

Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease.

Ana Beatriz Ayroza Galvão Ribeiro Gomes, Su-Hyun Kim, Roxanne Pretzsch, Laila Kulsvehagen, Sabine Schaedelin, Jasmine Lerner, Nora Sandrine Wetzel, Pascal Benkert, Aleksandra Maleska Maceski, Jae-Won Hyun and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Use of Fluid Biomarkers in NMOSD and MOGAD: Clinical and Research Applications.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Review
  2. Article
  3. Review
  4. Neuroglial markers of damage in autoimmune neurology.Therapeutic advances in neurological disorders · 2026
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ana Beatriz Ayroza Galvão Ribeiro GomesDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-1657-6891
Su-Hyun KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0002-0679-0918
Roxanne PretzschDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0009-0001-4129-1276
Laila KulsvehagenDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0001-5236-8323
Sabine SchaedelinDepartment of Clinical Research, Clinical Trial Unit, University of Basel, Basel, Switzerland; and.ORCID 0000-0002-1150-0962
Jasmine LernerDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0009-0003-7636-6930
Nora Sandrine WetzelDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-4991-4287
Pascal BenkertDepartment of Clinical Research, Clinical Trial Unit, University of Basel, Basel, Switzerland; and.ORCID 0000-0001-6525-8174
Aleksandra Maleska MaceskiDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-1916-5927
Jae-Won HyunDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0003-0288-771X
Anne-Catherine LecourtDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0009-0003-4174-4049
Patrick LippsDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0009-0002-5910-7622
Vinicius Andreoli SchoepsDepartamento de Neurologia, Instituto Central, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0001-8875-0567
Aline De Moura Brasil MatosDepartamento de Neurologia, Instituto Central, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0002-1854-2575
Natalia Trombini MendesDepartamento de Neurologia, Instituto Central, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0001-7104-0382
Samira Luisa Apóstolos-PereiraDepartamento de Neurologia, Instituto Central, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0003-3493-1199
Matthias MehlingDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0001-8599-1226
Tobias DerfussDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0001-8656-4250
Ludwig KapposResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0003-4175-5509
Dagoberto CallegaroDepartamento de Neurologia, Instituto Central, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0003-0077-173X
Jens KuhleDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-6963-8892
Ho Jin KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.ORCID 0000-0002-8672-8419
Anne-Katrin PröbstelDepartment of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-7748-1872

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), acute disease activity is generally identified through medical history, neurologic examination, and imaging. However, these may be insufficient for detecting disease activity in specific conditions. This study aimed to investigate the dynamics of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) after clinical attacks and to assess their utility in discriminating attacks from remission in patients with MOGAD.

methodsWe conducted a multicenter, retrospective, longitudinal study including 239 sera from 62 MOGAD patients assessed from 1995 to 2023 in a discovery and validation setup. Sera were measured for sNfL and sGFAP with a single-molecule array assay and for MOG-IgG with a live cell-based assay. sNfL and sGFAP Z scores and percentiles adjusted for age, body mass index, and sex (sGFAP) were calculated from a healthy control normative database. Mixed-effects regression models were used to characterize biomarkers' dynamics and to investigate associations between serum biomarkers, clinical variables, and disease activity status.

resultsAmong the 62 study participants, 29 (46.8%) were female, with a median age at baseline of 40.0 years (interquartile range [IQR] 29.5-49.8) and a median duration of follow-up of 20.0 months (IQR 3.0-62.8). sNfL and sGFAP Z scores were nonlinearly associated with time from attack onset ( DISCUSSION: sNfL Z scores may serve as a biomarker for monitoring disease activity in MOGAD.

Indexed as

BiomarkersMyelin-Oligodendrocyte GlycoproteinNeurofilament ProteinsAdultAutoantibodiesDemyelinating Autoimmune Diseases, CNSFemaleGlial Fibrillary Acidic ProteinHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesAutoantibodiesBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinMOG protein, humanMyelin-Oligodendrocyte Glycoproteinneurofilament protein LNeurofilament Proteins

Identifiers

PMID39705633
PMCPMC11666271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.